By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Dynamic Business Location.

Pfizer invests EUR 54 million in Austrian-based research

Pfizer building in Viennna © Pfizer

New medicines are being developed in cooperation with local medical universities, research institutions and hospitals. Clinical research carried out by Pfizer focuses on new treatments for cancer, chronic-inflammatory diseases, cardiovascular diseases, rare diseases, pain and new vaccines. In 2017 Pfizer also invested EUR 54 million in Austria.

One example of the company’s cooperation in the field of clinical research is its partnership with the academic institution ABCSG. The study group led by Prof. Michael Gnant (Medical University of Vienna) heads a registration trial with a substance developed by Pfizer to treat breast cancer. The study is completely financed by Pfizer and ABCSG is in charge of data, patient and project management in 21 countries across the globe. 5,600 patients are to take part in the study over a period of fifteen years. 18 hospitals and about 500 patients are involved just in Austria. „The fact that responsibility for a globally implemented Phase III study is in Austrian hands is a nice acknowledgement of the longstanding work done by ABCSG”, explains Prof. Gnant, President of ABCSG.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • 5. Mittelstandsforum Nordrhein-Westfalen

    26.11.2020/ 12:00 - 17:45, Online Conference

  • International Commercial & Legal Cooperation Forum

    03.12.2020, Shanghai, China

Austria Map

Find the perfect location for your company

Investments in research and innovation are the basis of success for our company. The business location of Austria offers us an attractive environment of development funding, non-university research facilities and access to optimally trained engineers and university progrlammes“, states Markus Staeblein, Managing Director of NXP Austria GmbH.

NXP Semiconductors Austria GmbH

Logo: NXP Semiconductors Austria GmbH
More testimonials

news from the business location Austria

Reopening of Human Factors Laboratory of Joanneum Research

Joanneum Research opened its newly designed Human Factors Laboratory.

Support measures for companies affected by COVID-19

To stimulate the economy, either new programs may be established as a result of the draft law or existing support programs (e.g. aws, ÖHT) will be expanded. All measures introduced are intended to be applicable immediately and will be in force until the end of 2020. The measures currently introduced include the following areas:

More news All blog posts